Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Cash & Equivalents (2017 - 2025)

X4 Pharmaceuticals filings provide 9 years of Cash & Equivalents readings, the most recent being $217.0 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 289.68% to $217.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $217.0 million, a 289.68% increase, with the full-year FY2025 number at $217.0 million, up 289.68% from a year prior.
  • Cash & Equivalents hit $217.0 million in Q4 2025 for X4 Pharmaceuticals, up from $69.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $217.0 million in Q4 2025 to a low of $39.2 million in Q2 2025.
  • Median Cash & Equivalents over the past 5 years was $87.6 million (2021), compared with a mean of $93.6 million.
  • The widest YoY moves for Cash & Equivalents: up 289.68% in 2025, down 73.36% in 2025.
  • X4 Pharmaceuticals' Cash & Equivalents stood at $81.8 million in 2021, then surged by 48.82% to $121.7 million in 2022, then decreased by 18.49% to $99.2 million in 2023, then tumbled by 43.86% to $55.7 million in 2024, then soared by 289.68% to $217.0 million in 2025.
  • The last three reported values for Cash & Equivalents were $217.0 million (Q4 2025), $69.6 million (Q3 2025), and $39.2 million (Q2 2025) per Business Quant data.